Endpoints Unveils 2023 List of Biopharma's Most Promising Startups

▎Edited by the WuXi AppTec content team

On September 20 local time in the United States, well-known industry media Endpoints released the "Biopharma's Most Promising Startups in 2023" list.11 Biotech Companies Made the List。These cutting-edge research areas include gene editing, precise drug delivery, epigenetic editing, artificial intelligence (AI)-driven drug discovery, cell therapy, gene sequencing, and more.This article will introduce these 11 rising companies (the following ranking is not in any particular order) to readers by combining this list with official information from each company.

Enveda Biosciences

Enveda Biosciences is a drug discovery company that develops small molecule therapies based on natural products by leveraging advanced machine learning, computational metabolomics, and knowledge graphs.Enveda is dedicated to using mass spectrometry and machine learning to discover new bioactive molecules. Its drug discovery search engine is built at the intersection of metabolomics and machine learning, storing data that includes novel molecules from nature as well as annotations on molecular properties, structures, and activities.The company has completed multiple rounds of financing so far. In April this year, Enveda completed a $51 million Series B1 financing round, which will use AI technology to advance natural small-molecule drugs into clinical trials.

Enveda initially aimed to tackle Wilson's disease, non-alcoholic steatohepatitis (NASH), and Parkinson’s disease but later shifted its focus to the fields of inflammation and immunology. Currently, Enveda's pipeline consists of 10 programs.The primary candidate therapy is an NLRP3 inflammasome inhibitor.Planning to enter clinical trials for inflammatory bowel disease next year. The company's second candidate therapy is a neutrophil-modulating oral drug, which will first be studied for use in atopic dermatitis.

Orbital Therapeutics

Orbital Therapeutics is an RNA therapy company formed by Beam Therapeutics, a star company in gene editing.Orbital Therapeutics aims to gather and integrate existing and emerging RNA technologies and delivery mechanisms to build a unique RNA technology platform.The goal of this platform is to extend the durability and half-life of innovative RNA therapies and deliver them to a variety of different cell and tissue types.Based on this platform, the company's R&D pipeline will include vaccines, immunomodulatory drugs, protein replacement therapies, and more.

In April this year, Orbital completed a $270 millionSeries A FinancingIn addition, Orbital Therapeutics has reached a research and development collaboration with Beam Therapeutics. Both parties will have the rights to use each other’s RNA technology and non-viral delivery technology. Beam Therapeutics has made several breakthroughs in RNA delivery technology based on lipid nanoparticles (LNPs). The company's LNP screening platform is capable of discovering LNP formulations that deliver RNA to different cells and tissues, and it has developed LNP formulations that can target mRNA delivery to T cells and natural killer cells.

AERA Therapeutics

Aera Therapeutics is a biotechnology company.Utilizing its proprietary Protein Nanoparticle (PNP) delivery platform, it is expected to precisely deliver various payloads such as gene therapy, mRNA, RNAi, antisense oligonucleotides (ASO), and gene editing systems to a wide range of human tissues and organs.`, significantly expanding the range of diseases these therapies can treat, benefiting more patients.`

The company has Professor Zhang Feng as its scientific founder, Dr. John Maraganore, the founding CEO of Alnylam, a star company in the RNAi field, as its chairman of the board, and Dr. Akin Akinc, who has been with Alnylam for nearly 20 years, as its CEO. The company is also supported by well-known venture capital institutions such as ARCH Venture Partner and GV, under Google. In March this year, Aera Therapeutics completed its Series A and B financing rounds, raising $193 million.

Chroma Medicine

Chroma Medicine aims to efficiently simulate epigenetic gene regulation mechanisms to precisely and durably control gene expression. Current gene editing methods regulate gene expression by modifying DNA sequences, which may introduce unintended genomic changes as it involves breaking the DNA.Chroma Medicine's epigenetic editing system couples DNA-binding domains with epigenetic effector domains, where the DNA-binding domain specifically targets individual or multiple genes that need to be silenced or activated, and the effector domain is responsible for regulating DNA methylation patterns, controlling chromatin conformation, and activating or suppressing gene expression. This method does not require cutting the DNA sequence or activating unpredictable DNA repair pathways, avoiding potential side effects caused by DNA sequence cleavage.。

Chroma Medicine completed a $125 million Series A financing in November 2021 and received an additional $135 million in March this year.Series B FinancingContinuing to develop its core epigenetic editing platform. In May this year, the company announced the potency of its epigenetic editing platform in vivo targeting two different targets including PCSK9. Data showed that this platform silenced 99% of target expression, successfully completing the task.Proof of Concept。

Isomorphic Labs

In November 2021, Alphabet, the parent company of Google, announced the establishment of Isomorphic Labs,The company will apply advanced AI deep learning methods to drug discovery, building on DeepMind's successful research in protein structure prediction.As early as 2020, DeepMind was already able to use its deep learning model, the AlphaFold artificial intelligence system, to accurately predict the 3D structure of proteins based on amino acid sequences. Its accuracy can rival 3D structures resolved using experimental techniques such as cryo-electron microscopy (CryoEM), nuclear magnetic resonance, or X-ray crystallography.

The traditional drug discovery process is time-consuming and has a low success rate; Isomorphic Labs believes that AI can improve this situation.The company focuses on building models of fundamental biological processes, using computers to predict how drugs will behave. Protein interactions, novel small molecule design, binding affinity, and toxicity analysis are all potential targets of its predictive models.

Immuneel Therapeutics

Immuneel Therapeutics is a pioneering startup dedicated to providing patients with high-quality, affordable cell therapies and achieving their accessibility worldwide. To achieve this goal,The company is introducing the next generation of cell therapy, aiming to revolutionize cancer treatment in an affordable way and bring hope to patients by leveraging bioengineered immune cells.The company completed a $15 million Series A financing round in June 2022.

Ultima Genomics

Ultima Genomics aims to unleash the power of genomics on a large scale, with a mission to continuously expand the scale of genomic information to achieve unprecedented progress in biology and improve human health.Ultima CompanyBy drawing on methods and materials frequently used in the semiconductor industry—standard silicon wafers—their sequencing instruments can accelerate read times while reducing costs, bringing the cost per sample down to around $100.。

The sequencing instruments developed by Ultima Genomics have been adopted by more than a dozen major research institutions, including the Broad Institute of Harvard and MIT, the New York Genome Center, Baylor College of Medicine, and the Sanger Institute. In addition, Ultima has reached an agreement with Regeneron, which acquired a stake in the company to help Ultima advance its second-generation sequencer. In June 2022, the company secured approximately $600 million in funding from investment firms, aiming to usher in a new era of genomics-driven research and healthcare.

Maze Therapeutics

Maze Therapeutics UtilizesNaturally occurring genetic variations and large-scale genetic screenings have uncovered disease-preventing genetic variants, paving the way for therapies based on these gene functions.Maze Therapeutics' research and development strategy is to explore the existing genetic diversity in humans, identify genetic variations that can reduce the risk of specific diseases, and then develop innovative therapies to mimic the effects of these genetic variations. In January 2022,Maze Therapeutics Announces Completion of $190 MillionFinancingTo advance the company's nine precision drug programs targeting genetically validated targets, treating both rare and common diseases.。

In March this year, Maze announced the Phase 1 clinical trial of its novel therapy MZE001 for Pompe disease conducted in healthy subjects.Positive ResultsThe results showed that MZE001 was well-tolerated in healthy subjects, with reduced glycogen accumulation in blood cells. These Phase 1 results support MZE001 advancing into the Phase 2 trial expected to initiate this year in Pompe disease patients.

Arsenal Biosciences（ArsenalBio）

ArsenalBio is a startup company dedicated to integrating technologies such as CRISPR gene editing, synthetic biology, and machine learning, and applying them to the development of immune cell therapies.

ArsenalBio's strategy combines CRISPR gene editing, synthetic biology, and logic-gated circuits to reprogram CAR-T cells.In September 2022, ArsenalBio announced the completion of a $220 million Series B financing to expand its programmable cell therapy research activities. In the same month, the company entered into a multi-year collaboration with Genentech, a subsidiary of Roche, which included a $70 million upfront payment. The collaboration focuses on high-throughput screening and T-cell engineering to identify key hubs for the success of T-cell-based therapies and to develop future solid tumor treatments.

The uniqueness of ArsenalBio's developed therapies lies in the ability to perform gene editing without the use of viral vectors.ArsenalBio's strategy encompasses three categories: developing non-viral, gene-edited autologous T cells for the treatment of solid tumors; establishing a database of instructions to determine the best ways to edit these cells; and collaborating with other companies.

The company's main project is AB-1015. Last November,ArsenalBio Initiates Phase 1 Clinical Trial of AB-1015 for the Treatment of Platinum-Resistant Epithelial Ovarian CancerDr. Ken Drazan, CEO of ArsenalBio, said in an interview with industry media Fierce Biotech last September,The company's second and third projects targeting kidney cancer and prostate cancer will be prepared to enter the clinical stage in early 2024 and early 2025, respectively.

ReNAgade Therapeutics

ReNAgade Therapeutics is an RNA therapy research and development company.What makes it unique is its delivery platform and proprietary tools, which can deliver RNA drugs to tissues and cells that were previously inaccessible.. This technology is reportedly able to help expand the current coverage of RNA drugs and is expected to be applied in the treatment of various diseases.

ReNAgade Therapeutics has built a comprehensive and complementary platform,The platform combines its proprietary delivery technologies, including novel lipid nanoparticles, as well as a broad range of RNA-based coding, editing, and gene insertion tools.ReNAgade Therapeutics aims to address the major limitations of RNA therapies by enabling the delivery of RNA drugs to previously inaccessible tissues and cells in the body, thereby expanding the range of potentially treatable diseases.

In May this year, ReNAgade Therapeutics announced the completion of a $300 million financing round led by MPM BioImpact and F2 Ventures.Series A FinancingThe funds will be used to advance the further development of preclinical and clinical pipelines for RNA drugs. According to a report by the industry media STAT at the time, ReNAgade Therapeutics' pipeline has completed in vitro and mouse experiments, and nearly 10 preclinical trials in non-human primates are currently underway.

Seismic Therapeutic

Seismic Therapeutic is a biotechnology company,Integrating Machine Learning into the Discovery Process of Biologics to Accelerate the Development of ImmunotherapiesIn February 2022, Seismic Therapeutic completed a $101 million Series A financing round.

Seismic Therapeutic's Proprietary IMPACT PlatformBy combining machine learning with structural biology, protein engineering, and translational immunology, it is possible to accelerate the design and analysis of a large number of proteins and protein modifications in parallel.This parallelized process simultaneously optimizes biological function and developability, creating novel biologics with superior properties while bypassing the trial-and-error approach of traditional biologics development and its challenges in balancing multiple efficacy and manufacturability factors. Seismic Therapeutic, Inc. has an emerging pipeline of biologics targeting dysregulation of the adaptive immune system to treat autoimmune diseases.